date:Apr 11, 2014
r. Hansen. I am especially pleased with the good performance of both the Cultures Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection.
Revenues for the first half year were 353 million, unchanged from first half 2012/13, with organic growth of 6%. EBIT before special items and impairments was 88 million and EBIT margin before special items and impairments 25.0%, both unchanged from last year
In the second quarter, revenue was 182